RESUMO
INTRODUCTION: Facial filling with hyaluronic acid (HA) is a dermatological procedure that has been emerging today. There are not many references regarding safety of reusing the remaining product for later touch-up in the same patient. OBJECTIVE: To determine the microbiological safety of reusing hyaluronic acid that is remnant from syringes used for facial filling, stored at room temperature or cooled in a refrigerator at 4°C. MATERIALS AND METHODS: In culture medium, small aliquots of leftovers from 31 hyaluronic acid fillers, previously used for facial filling, were inoculated. The fillers were stored in their original syringes at room temperature or cooled in a standard refrigerator at 4°C for a period ranging from 1 week to 12 months after initial use. LIMITATIONS: The small number of samples limits extrapolation of the results obtained. RESULTS: After 42 days of inoculation in culture medium, none of the samples showed any aerobic or anaerobic bacterial or fungal growth. CONCLUSION: Hyaluronic acid fillers did not show any fungal or bacterial contamination after being opened and stored at room temperature in nonaseptic conditions. The possibility of reusing the remaining portion of the material in the syringe can be safe and economically viable.
Assuntos
Preenchedores Dérmicos/efeitos adversos , Contaminação de Medicamentos , Ácido Hialurônico/efeitos adversos , Seringas/microbiologia , Contagem de Colônia Microbiana , Estudos Transversais , Armazenamento de Medicamentos/métodos , Face , Humanos , Rejuvenescimento , Retratamento , Envelhecimento da Pele , Fatores de TempoRESUMO
Subcutaneous phaeohyphomycosis is an infection caused by dematiaceous fungi which mainly affects immunosuppressed patients. We report a case of subcutaneous phaeohyphomycosis on the back of the left hand in a kidney transplant patient who had been taking prednisone, tacrolimus, and azathioprine daily for 3 years.
Assuntos
Dermatoses da Mão/patologia , Feoifomicose/patologia , Biópsia , Feminino , Dermatoses da Mão/cirurgia , Humanos , Hospedeiro Imunocomprometido , Terapia de Imunossupressão/efeitos adversos , Transplante de Rim , Pessoa de Meia-Idade , Feoifomicose/cirurgiaRESUMO
Drug-induced acne is a common skin condition whose classic symptoms can be similar to a rose pearl, as in the case of a male patient presenting with this condition after excessive use of a cream containing corticosteroids.
Assuntos
Acne Vulgar/induzido quimicamente , Acne Vulgar/diagnóstico , Corticosteroides/efeitos adversos , Toxidermias/diagnóstico , Diagnóstico Diferencial , Humanos , Masculino , Creme para a Pele/efeitos adversosRESUMO
Patients with mucocutaneous leishmaniasis (MCL) show a vigorous T-cell immune response against Leishmania braziliensis. Because the Th response is associated with inflammation, the non-functional CC chemokine receptor 5 (CCR5) may rely in a less severe inflammatory state. The aim of this study was to investigate the CCR5 gene in a Brazilian population with leishmaniasis compared with healthy control subjects and to determine the progression from cutaneous to MCL in the Delta32 allele carriers. Among 100 patients with Montenegro skin test and indirect immunofluorescence assay (IIF) values positive for leishmaniasis, there were 32% women and 68% men. The patients were 89% CCR5/CCR5, 10% CCR5/Delta32, and 1% Delta32/Delta32, while healthy subjects showed a 91% incidence of CCR5/CCR5, 8% of CCR5/Delta32, and 1% of Delta32/Delta32. The CCR5/CCR5 patients (89%) showed a large spectrum of clinical manifestations, where 22.47% had active mucous lesions and 77.53% had cutaneous lesions. In this work, the Delta32 allele carriers (10%) showed only cutaneous manifestations when compared with wild-type individuals. Finally, with regard to the Delta32 allele carriers, a less severe spectrum of clinical manifestations was observed in comparison with wild-type individuals. Although a lack of mucocutaneous lesions was evident among Delta32 allele carriers, the number of individuals studied was small. Therefore, further investigations are needed to elucidate the role of CCR5 in the clinical aspects of leishmaniasis.
Assuntos
Leishmaniose Cutânea/genética , Polimorfismo Genético , Receptores CCR5/genética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Alelos , Brasil , Criança , Pré-Escolar , Progressão da Doença , Feminino , Frequência do Gene , Heterozigoto , Humanos , Leishmaniose Cutânea/complicações , Leishmaniose Cutânea/patologia , Leishmaniose Mucocutânea/etiologia , Leishmaniose Mucocutânea/patologia , Masculino , Pessoa de Meia-Idade , Septo Nasal/patologia , Isoformas de Proteínas/genética , Índice de Gravidade de DoençaRESUMO
FUNDAMENTO: Dermatite esfoliativa é síndrome cutânea caracterizada por eritema e descamação generalizados, que pode ser conseqüente ou estar associada a várias doenças dermatológicas prévias, doenças sistêmicas ou reações medicamentosas. OBJETIVOS: Relatar a freqüência das diferentes causas e características clínicas associadas à dermatite esfoliativa nos pacientes atendidos no Setor de Dermatologia do Hospital Universitário Regional do Norte do Paraná, da Universidade Estadual de Londrina. MÉTODOS: Foram revisados os registros de pacientes com diagnóstico de dermatite esfoliativa diagnosticados no Hospital Universitário Regional do Norte do Paraná no período de 10 anos. RESULTADOS: Foi encontrado o total de 58 pacientes com diagnóstico de dermatite esfoliativa, com idade média de 56,89 anos. Em 33 pacientes, foi definida uma dermatose como causa (psoríase, 11 casos; dermatite de contato, nove casos; eritrodermia ictiosiforme congênita, três casos; dermatite seborréica, cinco casos; dermatite atópica, três casos; pitiríase rubra pilar, dois casos). Reações a drogas foram observadas em 11 pacientes. Em 14 casos (24 por cento) não foi possível determinar a causa básica. CONCLUSÕES: Numa amostra de pacientes atendidos num serviço de referência em dermatologia, a dermatite esfoliativa foi ocorrência pouco comum, e a maior parte dos casos estava relacionada a doenças dermatológicas.
RESUMO
Os autores realizam uma breve revisão sobre eritrodermia esfoliativa, que constitui uma síndrome que pode resultar de muitas causas diferentes. Doenças cutâneas prévias, doenças sistêmicas e reações às drogas tópicas ou sistêmicas podem ser causas de eritrodermia esfoliativa. Sintomas e sinais podem incluir prurido, fraqueza, hipotermia, perda de peso e descamação generalizada. A importância deste achado clínico são as complicações (debilidade e desidratação) e a possibilidade de ser manifestação de uma doença grave, como o linfoma cutâneo de células T
Assuntos
Humanos , Dermatite Esfoliativa , Diagnóstico DiferencialRESUMO
A total of 250 dentists (53.6 percent men and 46.4 percent women), with a mean age of 35.1 ± 9.8 years, were submitted to serological tests for the diagnosis of hepatitis B (HB) - HBsAg, anti-HBs, anti-HBc, HBeAg, and anti-HBe - using a radioimmunoassay. One or more of these markers were detected in 78 individuals (31.2 percent) who were excluded from the group to be vaccinated. Of the 172 HB-susceptible individuals, 135 (78.5 percent) responded to the call and were intradermally injected with three 2 µg doses of the Belgian HB recombinant vaccine, applied at an interval of one month between the 1st and 2nd dose and of five months between the 2nd and 3rd dose. A new determination of HB markers carried out 50 days after the 3rd dose showed that 110 (81.5 percent) individuals had become anti-HBs positive (65.5 percent good responders and 34.5 percent poor responders). Mean serum anti-HBs titer of these 110 dentists was 42.4 U S/N, similar in both sexes. The adverse effects analyzed in 106 dentists were: (a) local: pain (12.3 percent), burning sensation (14.1 percent), pruritus (25.5 percent), erythema (28.3 percent), local heat (18.9 percent), and a hypochromic spot (32.1 percent); (b) systemic (4.7 percent): discomfort in two patients, and fever, anorexia, and asthenia in one patient each. Intradermal administration of a fourth 2 µg vaccine dose to 39 dentists (poor or non-responders) increased the total number of anti-HBs-positive individuals from 110 (81.5 percent) to 114 (84.4 percent), with the number of good responders increasing from 72 (65.5 percent) to 85 (74.6 percent). We conclude that the Belgian recombinant vaccine applied in the scheme used here induces a high rate of seroconversion and causes only mild and transitory adverse effects.
Assuntos
Pessoa de Meia-Idade , Feminino , Adulto , Humanos , Masculino , Hepatite B , Anticorpos Anti-Hepatite B , Vacinas contra Hepatite B , Vírus da Hepatite B , Memória Imunológica , Biomarcadores , Odontólogos , Seguimentos , Hepatite B , Vacinas contra Hepatite B , Esquemas de Imunização , Técnicas Imunoenzimáticas , Memória Imunológica , Vacinas SintéticasRESUMO
Of the 110 dentists who had presented seroconversion 50 days after the intradermal application of three 2 µg doses of the Belgian recombinant vaccine against hepatitis B (HB), administered eight years before at an interval of one month between the 1st and 2nd doses and of five months between the 2nd and 3rd doses, 51 were included for the assessment of the persistence of immunity. None of the dentists had hepatitis or had received HB vaccine during this period. All subjects were submitted to serological tests for the detection of the following markers of hepatitis B virus (HBV) infection: HBsAg, anti-HBc, HBeAg, anti-HBe, and anti-HBs, with no HBsAg, anti-HBc, HBeAg or anti-HBe being detected. A microparticle enzyme immunoassay (MEIA) revealed the presence of anti-HBs at protective titers (> 10 mIU/ml) in 42 dentists (82.4 percent), with the anti-HBs titer being higher than 100 mIU/ml in 36 of them (70.6 percent) (good responders), between 10 and 100 mIU/ml in 6 (11.8 percent) (poor responders), and lower than 10 mIU/ml in 9 (17.6 percent) (non-responders). According to clinical data and serological tests, none of the dentists had presented disease or latent HBV infection during the eight years following the first vaccination. A 2 µg booster dose was administered intradermally to eight dentists with anti-HBs titers lower than 10 mIU/ml (non-responders) and to six dentists with titers ranging from 10 to 100 mIU/ml (poor responders); the determination of anti-HBs one month later demonstrated the occurrence of seroconversion in the eight non-responders and an increase in anti-HBs titer in the six poor responders. In summary, the present results demonstrated the prolonged persistence of protection against HBV infection and the development of immunologic memory provided by vaccination against HB - with intra-dermal application of three 2 µg doses of the Belgian recombinant vaccine at 0, 1, and 6 months - carried out eight years before in 51 dentists.
Assuntos
Pessoa de Meia-Idade , Adulto , Feminino , Humanos , Masculino , Hepatite B , Anticorpos Anti-Hepatite B , Vacinas contra Hepatite B , Vírus da Hepatite B , Memória Imunológica , Idoso de 80 Anos ou mais , Biomarcadores , Odontólogos , Seguimentos , Vacinas contra Hepatite B , Esquemas de Imunização , Memória Imunológica , Vacinas SintéticasRESUMO
A total of 250 dentists (53.6% men and 46.4% women), with a mean age of 35.1 +/- 9.8 years, were submitted to serological tests for the diagnosis of hepatitis B (HB)--HBsAg, anti-HBs, anti-HBc, HBeAg, and anti-HBe--using a radioimmunoassay. One or more of these markers were detected in 78 individuals (31.2%) who were excluded from the group to be vaccinated. Of the 172 HB-susceptible individuals, 135 (78.5%) responded to the call and were intradermally injected with three 2 micrograms doses of the Belgian HB recombinant vaccine, applied at an interval of one month between the 1st and 2nd dose and of five months between the 2nd and 3rd dose. A new determination of HB markers carried out 50 days after the 3rd dose showed that 110 (81.5%) individuals had become anti-HBs positive (65.5% good responders and 34.5% poor responders). Mean serum anti-HBs titer of these 110 dentists was 42.4 U S/N, similar in both sexes. The adverse effects analyzed in 106 dentists were: (a) local: pain (12.3%), burning sensation (14.1%), pruritus (25.5%), erythema (28.3%), local heat (18.9%), and a hypochromic spot (32.1%); (b) systemic (4.7%): discomfort in two patients, and fever, anorexia, and asthenia in one patient each. Intradermal administration of a fourth 2 micrograms vaccine dose to 39 dentists (poor or non-responders) increased the total number of anti-HBs-positive individuals from 110 (81.5%) to 114 (84.4%), with the number of good responders increasing from 72 (65.5%) to 85 (74.6%). We conclude that the Belgian recombinant vaccine applied in the scheme used here induces a high rate of seroconversion and causes only mild and transitory adverse effects.